Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAmerican Oncology Network, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | N/A | -$0.19 | N/A | N/A | $470.28 M |
| 08/14/2024 | Q2 2024 | N/A | $0.12 | N/A | N/A | $433.98 M |
| 03/30/2024 | Q1 2024 | N/A | -$1.22 | N/A | N/A | $364.34 M |
| 12/30/2023 | Q4 2023 | N/A | -$0.56 | N/A | N/A | $324.18 M |
| 09/29/2023 | Q3 2023 | N/A | -$0.61 | N/A | N/A | $336.31 M |
| 06/28/2023 | Q2 2023 | N/A | -$0.17 | N/A | N/A | $314.97 M |
| 05/12/2023 | Q1 2023 | N/A | $0.01 | N/A | N/A | $303.73 M |
| 12/30/2022 | Q4 2022 | N/A | $0.27 | N/A | N/A | $300.40 M |
| 09/29/2022 | Q3 2022 | N/A | $0.36 | N/A | N/A | $297.32 M |
| 08/12/2022 | Q2 2022 | N/A | $0.04 | N/A | N/A | $0 |
| 05/17/2022 | Q1 2022 | N/A | $0.08 | N/A | N/A | $0 |
| 04/13/2022 | Q4 2021 | N/A | -$0.01 | N/A | N/A | $0 |
| 11/19/2021 | Q3 2021 | N/A | $0.08 | N/A | N/A | $0 |
| 08/24/2021 | Q2 2021 | N/A | $0.20 | N/A | N/A | $0 |
| 03/30/2021 | Q1 2021 | N/A | -$0.01 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
American Oncology Network, Inc. Earnings: FAQ's
The conference call for American Oncology Network, Inc.'s latest earnings report can be listened to online.
The conference call transcript for American Oncology Network, Inc.'s latest earnings report can be read online.
American Oncology Network, Inc. (:AONC) has a recorded annual revenue of $1.28 B.
American Oncology Network, Inc. (:AONC) has a recorded net income of $-5,542,000.American Oncology Network, Inc. has generated $-1.36 earnings per share over the last four quarters.
American Oncology Network, Inc. (:AONC) has a price-to-earnings ratio of -5.88 and price/earnings-to-growth ratio is -0.32.